Your Cart is Empty
In the evolving landscape of diabetes management and weight loss, a new compound called retatrutide has emerged that reigns supreme over past weight loss contenders such as Ozempic.
This article aims to provide a detailed comparison between Retatrutide and Ozempic, focusing on their effectiveness and the outcomes for patients.
Retatrutide is a newer compound trialled for the treatment of type 2 diabetes and obesity. Its formulation is based on a unique combination of compounds that target specific pathways in the body. The mechanism of action of Retatrutide involves enhancing insulin sensitivity and promoting glucose uptake in the body, making it an effective tool in blood sugar management.
Ozempic, known generically as semaglutide, is widely used in the treatment of type 2 diabetes. It belongs to a class of drugs known as GLP-1 receptor agonists. Ozempic works by stimulating insulin production and reducing the amount of glucose released by the liver, which aids in lowering blood sugar levels and supports weight loss.
Lilly’s phase 2 trial looked at 338 adults who were obese or overweight and were randomized to receive a placebo or one of four dosages of retatrutide. (1,2,4,8mg per week) The drug was given as a weekly injection and Participants had a body mass index, or BMI, of 27 or greater.
After 24 weeks, patients taking the highest dose lost, on average, 17.5% of their body weight, the equivalent of, on average, 41 pounds, according to the company. By 48 weeks, the weight loss increased to 24.2% of their body, or 57.8 pounds.
“The degree of efficacy, it was definitely striking,” said Dr. Ania Jastreboff, an obesity medicine physician scientist at Yale University School of Medicine and the lead author on the phase 2 study.
Retatrutide differs from other compounds by targeting three hunger-regulating hormones, unlike Ozempic and Wegovy which only target the glucagon-like peptide-1 (GLP-1) receptors, important in diabetes and weight loss treatments.
Retatrutide also mimics the glucose-dependent insulinotropic polypeptide (GIP) hormone and goes further by also affecting the glucagon receptor, which is involved in regulating glucose and lipid metabolism, thus aiding weight loss. This "triple G" effect may be its unique advantage. Studies show Retatrutide can induce weight loss of up to 24.2% after 48 weeks, while semaglutide (Wegovy and Ozempic's generic form) has a reduction potential of around 15% after 68 weeks.
What's particularly encouraging is that these results were achieved in individuals who have historically struggled with weight management, indicating that Retatrutide could be a viable solution for those who have found little success with traditional methods of dieting and exercise. This factor alone could make it a game-changer for many.
Those who are experienced in dieting, training and all other aspects will find it much easier.
As we've seen, Retatrutide emerges as a promising contender in the arena of weight loss and diabetes management. The results from Lilly's phase 2 trial are particularly noteworthy, demonstrating significant weight loss in participants. With an average loss of 17.5% body weight within 24 weeks, and an impressive 24.2% by 48 weeks, Retatrutide stands out not just for its effectiveness and its speed of weight loss, but also for the potential for sustained weight loss over time.
Retatrutide might just be the key to unlocking a healthier, more manageable lifestyle for those who have been searching for a solution to their weight loss and diabetes management challenges.
We encourage anyone interested in exploring this treatment option to consult with their healthcare provider.
*The content provided on this website is for informational purposes only and should not be considered as medical advice, diagnosis, or treatment. Any statements regarding health improvements have not been evaluated by the Therapeutic Goods Administration (TGA)